Click for best price
Tumor Immunity Therapy Market Size, Share 2023
This report aims to provide a comprehensive presentation of the global market for Tumor Immunity Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Immunity Therapy. This report contains market size and forecasts of Tumor Immunity Therapy in global, including the following market information:
Global Tumor Immunity Therapy Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Tumor Immunity Therapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Immune Checkpoint Inhibitor Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Tumor Immunity Therapy include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc. and IMVAQ Therapeutics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Tumor Immunity Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Tumor Immunity Therapy Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Tumor Immunity Therapy Market Segment Percentages, by Type, 2022 (%)
Immune Checkpoint Inhibitor
Cytokine Immunotherapy
Cancer Vaccine
Car-t Cell Therapy
Others
Global Tumor Immunity Therapy Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Tumor Immunity Therapy Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Global Tumor Immunity Therapy Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Tumor Immunity Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Tumor Immunity Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Tumor Immunity Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
IMVAQ Therapeutics
Arch Oncology
Juno Therapeutics
Refuge
Lepu Biopharma
Genoimmune
TCR Cure
Outline of Major Chapters:
Chapter 1: Introduces the definition of Tumor Immunity Therapy, market overview.
Chapter 2: Global Tumor Immunity Therapy market size in revenue.
Chapter 3: Detailed analysis of Tumor Immunity Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Tumor Immunity Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Tumor Immunity Therapy Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
106 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Tumor Immunity Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Tumor Immunity Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Tumor Immunity Therapy Overall Market Size
2.1 Global Tumor Immunity Therapy Market Size: 2022 VS 2030
2.2 Global Tumor Immunity Therapy Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Tumor Immunity Therapy Players in Global Market
3.2 Top Global Tumor Immunity Therapy Companies Ranked by Revenue
3.3 Global Tumor Immunity Therapy Revenue by Companies
3.4 Top 3 and Top 5 Tumor Immunity Therapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Tumor Immunity Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Tumor Immunity Therapy Players in Global Market
3.6.1 List of Global Tier 1 Tumor Immunity Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Tumor Immunity Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Tumor Immunity Therapy Market Size Markets, 2022 & 2030
4.1.2 Immune Checkpoint Inhibitor
4.1.3 Cytokine Immunotherapy
4.1.4 Cancer Vaccine
4.1.5 Car-t Cell Therapy
4.1.6 Others
4.2 By Type - Global Tumor Immunity Therapy Revenue & Forecasts
4.2.1 By Type - Global Tumor Immunity Therapy Revenue, 2018-2023
4.2.2 By Type - Global Tumor Immunity Therapy Revenue, 2024-2030
4.2.3 By Type - Global Tumor Immunity Therapy Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Tumor Immunity Therapy Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Clinic
5.2 By Application - Global Tumor Immunity Therapy Revenue & Forecasts
5.2.1 By Application - Global Tumor Immunity Therapy Revenue, 2018-2023
5.2.2 By Application - Global Tumor Immunity Therapy Revenue, 2024-2030
5.2.3 By Application - Global Tumor Immunity Therapy Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Tumor Immunity Therapy Market Size, 2022 & 2030
6.2 By Region - Global Tumor Immunity Therapy Revenue & Forecasts
6.2.1 By Region - Global Tumor Immunity Therapy Revenue, 2018-2023
6.2.2 By Region - Global Tumor Immunity Therapy Revenue, 2024-2030
6.2.3 By Region - Global Tumor Immunity Therapy Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Tumor Immunity Therapy Revenue, 2018-2030
6.3.2 US Tumor Immunity Therapy Market Size, 2018-2030
6.3.3 Canada Tumor Immunity Therapy Market Size, 2018-2030
6.3.4 Mexico Tumor Immunity Therapy Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Tumor Immunity Therapy Revenue, 2018-2030
6.4.2 Germany Tumor Immunity Therapy Market Size, 2018-2030
6.4.3 France Tumor Immunity Therapy Market Size, 2018-2030
6.4.4 U.K. Tumor Immunity Therapy Market Size, 2018-2030
6.4.5 Italy Tumor Immunity Therapy Market Size, 2018-2030
6.4.6 Russia Tumor Immunity Therapy Market Size, 2018-2030
6.4.7 Nordic Countries Tumor Immunity Therapy Market Size, 2018-2030
6.4.8 Benelux Tumor Immunity Therapy Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Tumor Immunity Therapy Revenue, 2018-2030
6.5.2 China Tumor Immunity Therapy Market Size, 2018-2030
6.5.3 Japan Tumor Immunity Therapy Market Size, 2018-2030
6.5.4 South Korea Tumor Immunity Therapy Market Size, 2018-2030
6.5.5 Southeast Asia Tumor Immunity Therapy Market Size, 2018-2030
6.5.6 India Tumor Immunity Therapy Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Tumor Immunity Therapy Revenue, 2018-2030
6.6.2 Brazil Tumor Immunity Therapy Market Size, 2018-2030
6.6.3 Argentina Tumor Immunity Therapy Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Tumor Immunity Therapy Revenue, 2018-2030
6.7.2 Turkey Tumor Immunity Therapy Market Size, 2018-2030
6.7.3 Israel Tumor Immunity Therapy Market Size, 2018-2030
6.7.4 Saudi Arabia Tumor Immunity Therapy Market Size, 2018-2030
6.7.5 UAE Tumor Immunity Therapy Market Size, 2018-2030
7 Tumor Immunity Therapy Companies Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Company Summary
7.1.2 Bristol-Myers Squibb Business Overview
7.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Major Product Offerings
7.1.4 Bristol-Myers Squibb Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.1.5 Bristol-Myers Squibb Key News & Latest Developments
7.2 Merck & Co., Inc.
7.2.1 Merck & Co., Inc. Company Summary
7.2.2 Merck & Co., Inc. Business Overview
7.2.3 Merck & Co., Inc. Tumor Immunity Therapy Major Product Offerings
7.2.4 Merck & Co., Inc. Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.2.5 Merck & Co., Inc. Key News & Latest Developments
7.3 Roche AG
7.3.1 Roche AG Company Summary
7.3.2 Roche AG Business Overview
7.3.3 Roche AG Tumor Immunity Therapy Major Product Offerings
7.3.4 Roche AG Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.3.5 Roche AG Key News & Latest Developments
7.4 AstraZeneca, Plc
7.4.1 AstraZeneca, Plc Company Summary
7.4.2 AstraZeneca, Plc Business Overview
7.4.3 AstraZeneca, Plc Tumor Immunity Therapy Major Product Offerings
7.4.4 AstraZeneca, Plc Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.4.5 AstraZeneca, Plc Key News & Latest Developments
7.5 Sanofi S.A.
7.5.1 Sanofi S.A. Company Summary
7.5.2 Sanofi S.A. Business Overview
7.5.3 Sanofi S.A. Tumor Immunity Therapy Major Product Offerings
7.5.4 Sanofi S.A. Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.5.5 Sanofi S.A. Key News & Latest Developments
7.6 Dendreon Pharmaceuticals
7.6.1 Dendreon Pharmaceuticals Company Summary
7.6.2 Dendreon Pharmaceuticals Business Overview
7.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Major Product Offerings
7.6.4 Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.6.5 Dendreon Pharmaceuticals Key News & Latest Developments
7.7 Novartis
7.7.1 Novartis Company Summary
7.7.2 Novartis Business Overview
7.7.3 Novartis Tumor Immunity Therapy Major Product Offerings
7.7.4 Novartis Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.7.5 Novartis Key News & Latest Developments
7.8 Gilead Sciences Inc.
7.8.1 Gilead Sciences Inc. Company Summary
7.8.2 Gilead Sciences Inc. Business Overview
7.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Major Product Offerings
7.8.4 Gilead Sciences Inc. Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.8.5 Gilead Sciences Inc. Key News & Latest Developments
7.9 IMVAQ Therapeutics
7.9.1 IMVAQ Therapeutics Company Summary
7.9.2 IMVAQ Therapeutics Business Overview
7.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Major Product Offerings
7.9.4 IMVAQ Therapeutics Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.9.5 IMVAQ Therapeutics Key News & Latest Developments
7.10 Arch Oncology
7.10.1 Arch Oncology Company Summary
7.10.2 Arch Oncology Business Overview
7.10.3 Arch Oncology Tumor Immunity Therapy Major Product Offerings
7.10.4 Arch Oncology Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.10.5 Arch Oncology Key News & Latest Developments
7.11 Juno Therapeutics
7.11.1 Juno Therapeutics Company Summary
7.11.2 Juno Therapeutics Business Overview
7.11.3 Juno Therapeutics Tumor Immunity Therapy Major Product Offerings
7.11.4 Juno Therapeutics Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.11.5 Juno Therapeutics Key News & Latest Developments
7.12 Refuge
7.12.1 Refuge Company Summary
7.12.2 Refuge Business Overview
7.12.3 Refuge Tumor Immunity Therapy Major Product Offerings
7.12.4 Refuge Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.12.5 Refuge Key News & Latest Developments
7.13 Lepu Biopharma
7.13.1 Lepu Biopharma Company Summary
7.13.2 Lepu Biopharma Business Overview
7.13.3 Lepu Biopharma Tumor Immunity Therapy Major Product Offerings
7.13.4 Lepu Biopharma Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.13.5 Lepu Biopharma Key News & Latest Developments
7.14 Genoimmune
7.14.1 Genoimmune Company Summary
7.14.2 Genoimmune Business Overview
7.14.3 Genoimmune Tumor Immunity Therapy Major Product Offerings
7.14.4 Genoimmune Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.14.5 Genoimmune Key News & Latest Developments
7.15 TCR Cure
7.15.1 TCR Cure Company Summary
7.15.2 TCR Cure Business Overview
7.15.3 TCR Cure Tumor Immunity Therapy Major Product Offerings
7.15.4 TCR Cure Tumor Immunity Therapy Revenue in Global Market (2018-2023)
7.15.5 TCR Cure Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Tumor Immunity Therapy Market Opportunities & Trends in Global Market
Table 2. Tumor Immunity Therapy Market Drivers in Global Market
Table 3. Tumor Immunity Therapy Market Restraints in Global Market
Table 4. Key Players of Tumor Immunity Therapy in Global Market
Table 5. Top Tumor Immunity Therapy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Tumor Immunity Therapy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Tumor Immunity Therapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies Tumor Immunity Therapy Product Type
Table 9. List of Global Tier 1 Tumor Immunity Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Tumor Immunity Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Tumor Immunity Therapy Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Tumor Immunity Therapy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Tumor Immunity Therapy Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Tumor Immunity Therapy Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Tumor Immunity Therapy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Tumor Immunity Therapy Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Tumor Immunity Therapy Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Tumor Immunity Therapy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Tumor Immunity Therapy Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Tumor Immunity Therapy Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Tumor Immunity Therapy Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Tumor Immunity Therapy Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Tumor Immunity Therapy Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Tumor Immunity Therapy Revenue, (US$, Mn), 2024-2030
Table 30. Bristol-Myers Squibb Company Summary
Table 31. Bristol-Myers Squibb Tumor Immunity Therapy Product Offerings
Table 32. Bristol-Myers Squibb Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 33. Bristol-Myers Squibb Key News & Latest Developments
Table 34. Merck & Co., Inc. Company Summary
Table 35. Merck & Co., Inc. Tumor Immunity Therapy Product Offerings
Table 36. Merck & Co., Inc. Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 37. Merck & Co., Inc. Key News & Latest Developments
Table 38. Roche AG Company Summary
Table 39. Roche AG Tumor Immunity Therapy Product Offerings
Table 40. Roche AG Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 41. Roche AG Key News & Latest Developments
Table 42. AstraZeneca, Plc Company Summary
Table 43. AstraZeneca, Plc Tumor Immunity Therapy Product Offerings
Table 44. AstraZeneca, Plc Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 45. AstraZeneca, Plc Key News & Latest Developments
Table 46. Sanofi S.A. Company Summary
Table 47. Sanofi S.A. Tumor Immunity Therapy Product Offerings
Table 48. Sanofi S.A. Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 49. Sanofi S.A. Key News & Latest Developments
Table 50. Dendreon Pharmaceuticals Company Summary
Table 51. Dendreon Pharmaceuticals Tumor Immunity Therapy Product Offerings
Table 52. Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 53. Dendreon Pharmaceuticals Key News & Latest Developments
Table 54. Novartis Company Summary
Table 55. Novartis Tumor Immunity Therapy Product Offerings
Table 56. Novartis Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 57. Novartis Key News & Latest Developments
Table 58. Gilead Sciences Inc. Company Summary
Table 59. Gilead Sciences Inc. Tumor Immunity Therapy Product Offerings
Table 60. Gilead Sciences Inc. Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 61. Gilead Sciences Inc. Key News & Latest Developments
Table 62. IMVAQ Therapeutics Company Summary
Table 63. IMVAQ Therapeutics Tumor Immunity Therapy Product Offerings
Table 64. IMVAQ Therapeutics Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 65. IMVAQ Therapeutics Key News & Latest Developments
Table 66. Arch Oncology Company Summary
Table 67. Arch Oncology Tumor Immunity Therapy Product Offerings
Table 68. Arch Oncology Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 69. Arch Oncology Key News & Latest Developments
Table 70. Juno Therapeutics Company Summary
Table 71. Juno Therapeutics Tumor Immunity Therapy Product Offerings
Table 72. Juno Therapeutics Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 73. Juno Therapeutics Key News & Latest Developments
Table 74. Refuge Company Summary
Table 75. Refuge Tumor Immunity Therapy Product Offerings
Table 76. Refuge Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 77. Refuge Key News & Latest Developments
Table 78. Lepu Biopharma Company Summary
Table 79. Lepu Biopharma Tumor Immunity Therapy Product Offerings
Table 80. Lepu Biopharma Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 81. Lepu Biopharma Key News & Latest Developments
Table 82. Genoimmune Company Summary
Table 83. Genoimmune Tumor Immunity Therapy Product Offerings
Table 84. Genoimmune Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 85. Genoimmune Key News & Latest Developments
Table 86. TCR Cure Company Summary
Table 87. TCR Cure Tumor Immunity Therapy Product Offerings
Table 88. TCR Cure Tumor Immunity Therapy Revenue (US$, Mn) & (2018-2023)
Table 89. TCR Cure Key News & Latest Developments
List of Figures
Figure 1. Tumor Immunity Therapy Segment by Type in 2022
Figure 2. Tumor Immunity Therapy Segment by Application in 2022
Figure 3. Global Tumor Immunity Therapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Tumor Immunity Therapy Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Tumor Immunity Therapy Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Tumor Immunity Therapy Revenue in 2022
Figure 8. By Type - Global Tumor Immunity Therapy Revenue Market Share, 2018-2030
Figure 9. By Application - Global Tumor Immunity Therapy Revenue Market Share, 2018-2030
Figure 10. By Type - Global Tumor Immunity Therapy Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Tumor Immunity Therapy Revenue Market Share, 2018-2030
Figure 12. By Application - Global Tumor Immunity Therapy Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Tumor Immunity Therapy Revenue Market Share, 2018-2030
Figure 14. By Region - Global Tumor Immunity Therapy Revenue Market Share, 2018-2030
Figure 15. By Country - North America Tumor Immunity Therapy Revenue Market Share, 2018-2030
Figure 16. US Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Tumor Immunity Therapy Revenue Market Share, 2018-2030
Figure 20. Germany Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 21. France Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Tumor Immunity Therapy Revenue Market Share, 2018-2030
Figure 28. China Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 32. India Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Tumor Immunity Therapy Revenue Market Share, 2018-2030
Figure 34. Brazil Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Tumor Immunity Therapy Revenue Market Share, 2018-2030
Figure 37. Turkey Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Tumor Immunity Therapy Revenue, (US$, Mn), 2018-2030
Figure 41. Bristol-Myers Squibb Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck & Co., Inc. Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Roche AG Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. AstraZeneca, Plc Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Sanofi S.A. Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Novartis Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Gilead Sciences Inc. Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. IMVAQ Therapeutics Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Arch Oncology Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Juno Therapeutics Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Refuge Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Lepu Biopharma Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Genoimmune Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. TCR Cure Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
